- Roche continues to increase access to accurate, timely and reliable diagnostics in the fight against COVID-19 by expanding the COVID-19 PCR portfolio on the cobas 5800 System
- These tests are for the qualitative detection of SARS-CoV-2 and the qualitative detection and differentiation of SARS-CoV-2, influenza A virus, and/or influenza B virus
- As communities across the globe still need effective solutions for COVID-19, Roche will continue to invest in diagnostics to ensure there are testing options available to healthcare communities and patients worldwide
PR Newswire
PLEASANTON, Calif., Feb. 23, 2022